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Abstract
The obligate aerobic yeast Yarrowia lipolytica is introduced as a powerful new model for the structural and functional analysis of
mitochondrial complex I. A brief introduction into the biology and the genetics of this nonconventional yeast is given and the relevant genetic
tools that have been developed in recent years are summarized. The respiratory chain of Y. lipolytica contains complexes I–IV, one
‘‘alternative’’ NADH-dehydrogenase (NDH2) and a non-heme alternative oxidase (AOX). Because the NADH binding site of NDH2 faces
the mitochondrial intermembrane space rather than the matrix, complex I is an essential enzyme in Y. lipolytica. Nevertheless, complex I
deletion strains could be generated by attaching the targeting sequence of a matrix protein, thereby redirecting NDH2 to the matrix side.
Deletion strains for several complex I subunits have been constructed that can be complemented by shuttle plasmids carrying the deleted
gene. Attachment of a hexa-histidine tag to the NUGM (30 kDa) subunit allows fast and efficient purification of complex I from Y. lipolytica
by affinity-chromatography. The purified complex has lost most of its NADH:ubiquinone oxidoreductase activity, but is almost fully
reactivated by adding 400–500 molecules of phosphatidylcholine per complex I. The established set of genetic tools has proven useful for
the site-directed mutagenesis of individual subunits of Y. lipolytica complex I. Characterization of a number of mutations already allowed for
the identification of several functionally important amino acids, demonstrating the usefulness of this approach.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
With 43 subunits in mammals [1–3], at least 35 subunits
in fungi [4] and 13 to 14 subunits in procaryotes [5],
complex I (NADH:ubiquinone oxidoreductase) is the largest
and most complicated enzyme of the respiratory chain. It
contributes up to 40% of the proton gradient across the
mitochondrial membrane [6], is a prime source for oxygen
radicals produced in the mitochondrial matrix [7] and is the
target site for numerous mutations leading to mitochondrial
dysfunction in humans [8–11]. Yet, very little is known
about its reaction mechanism, especially the interaction with
ubiquinone and the coupling of electron transport and
proton translocation [12,13]. This is at least partly due to
the lack of a convenient genetic approach to study the
structure and function of this impressive enzyme complex.
Here we present Yarrowia lipolytica, a nonconventional
yeast for which a comprehensive set of well-developed
genetic tools is available, as a powerful new model system
for the structural and functional analysis of complex I.
2. What is Y. lipolytica?
Y. lipolytica, a dimorphic, heterothallic, ascomycetous
yeast, is an obligate aerobe with a unique capability to
utilize aliphatic carbon sources, including fatty acids and
alkanes. This is in stark contrast to Saccharomyces cerevi-
siae, which prefers ethanolic fermentation, rather than
respiration as mode of glucose utilization, even in the
presence of oxygen [14]. In keeping with its saprophytic
lifestyle, Y. lipolytica is proficient in secreting extracellular
lipases [15], acid [16] and alkaline [17] proteases and
RNAse [18,19].
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A small but very active and interactive community has
been working on this nonconventional yeast, both on
applied and basic research oriented topics. Reviews on Y.
lipolytica as an experimental system can be found in Refs.
[20,21].
Interest in Y. lipolytica has received a major boost by its
usefulness for biotechnological applications. Apart from a
certain role in traditional food technology, like the pro-
cessing of cheese and other diary products [22,23], this
yeast has been exploited for the production of single-cell
protein for animal feeds, for the production of organic
compounds like citric acid [24] and a-ketoglutaric acid
[25] and for bioconversions of aliphatic compounds, e.g.
the production of g-decalactone, a peachy aroma com-
pound resulting from the peroxisomal beta-oxidation of
ricinoleic acid [26].
Another emerging issue is the secretion of recombinant
proteins. Vectors have been constructed that allow for the N-
terminal fusion of the secretion signal of the extracellular
alkaline protease (XPR2) to heterologous proteins. For high-
level expression, a strong hybrid promoter consisting of four
copies of an upstream activator sequence (UAS1) from the
XPR2 locus [27], fused to the LEU2 minimal promoter, can
be used. In a comparative study, Y. lipolytica outmatched
other yeast species since it consistently showed good to
excellent secretion of a number of model proteins [28].
Protein expression in this organism does not require induc-
tion with methanol, which makes Y. lipolytica a favourable
expression system for proteins intended for use in food
technology.
Some of the research efforts that have benefited from
the unique physiological properties of Y. lipolytica may
be highlighted briefly here: Peroxisome biogenesis can be
induced by shifting from glucose to acetate or aliphatic
carbon sources [29,30]. Similarly, peroxisome degradation
is triggered by shifting from acetate/oleate/ethylamine into
glucose plus ammonium sulfate-containing media [31].
Among many others, the pex16-1 strain was isolated in
a screen for the inability to utilize oleic acid as a sole
carbon source [32]. The Arabidopsis thaliana shrunken
seed 1(sse1) gene was able to restore growth on oleic
acid to the Y. lipolytica pex16-1 mutant strain [33],
pointing at fundamental similarities between the roles of
the two proteins in oil body and peroxisome biogenesis,
respectively. The Y. lipolytica PEX16 gene was found to
encode a yet unknown intraperoxisomal peripheral mem-
brane protein. Using this gene as a probe, the human
homologue was isolated from a liver cDNA library,
which was then shown to underlie one form of Zellweger
syndrome [34].
Single-cell to hyphae transition has been associated with
pathogenesis in Candida albicans [35]. Studies in the non-
pathogenic model organism Y. lipolytica have revealed
several genes that are essential for filament formation
[36–39]. These studies may help to identify novel targets
for the development of antifungal drugs.
3. Y. lipolytica genetic tools
After the discovery of sexual reproduction in Candida
lipolytica [40], the species was first renamed Saccharomy-
copsis lipolytica and later Yarrowia lipolytica [41]. Most
natural isolates of Y. lipolytica are in the haploid state and
grow vegetatively [40]. Mating frequency and spore viabil-
ity are low, even with laboratory strains that were made
isogenic by inbreeding. Y. lipolytica is heterothallic and both
mating type alleles, MatA [42] and MatB [Kurischko,
personal communication], have been cloned. Silent cassettes
or mating type switching, as in S. cerevisiae [43], have
never been observed.
A number of classical mutants (auxotrophies for amino
acids and nucleotides, resistance to antibiotics and antime-
tabolites, colour and colony morphology mutants) were
isolated following mutagenesis by UV-light or alkylating
agents [44]. The use of resistance genes as dominant
markers is problematic, since Y. lipolytica is naturally
resistant against a variety of antibiotics like chlorampheni-
col and G418 [45] and the broad-range biozide BASTA
(Kerscher, unpublished observation). However, the hygrom-
ycin B phosphotransferase (hph) gene from E. coli [46] has
been used successfully as resistance marker [45,47].
Inbred strains have been developed in several laborato-
ries. The E129 (MatA, lys11-23, ura3-302, leu2-270, xpr2-
322) and E150 (MatB, his-1, ura3-302, leu2-270, xpr2-322)
strains (the latter strain is also the standard used in the Y.
lipolytica genome project) carry nonreverting alleles of ura3
and leu2 that have been generated by the pop-in-pop-out
strategy [20,21].
Low-copy plasmids that are based on chromosomal
ARS/CEN regions [48] have been developed, which are
useful tools to study the effects of in-vitro mutagenized
genes when expressed at a level comparable to the original
chromosomal context. Several strong and regulated pro-
moters are known, including the XPR2 [49], ICL1 [50],
POX2 [51] and POT1 [52] promoters. Using the ICL1
(isocitrate lyase 1, a gene from the anaplerotic glyoxylate
cycle) promoter an 8–14-fold increase in target protein
expression was observed when glucose-grown cells were
transferred into ethanol- acetate- or alkane-containing
medium [53]. High transgene copy numbers can be achieved
by targeting chromosomal integration to the LTR of the
retrotransposon Ylt1 [54]. A promoter-deficient URA3
marker gene has been constructed that allows for the screen-
ing of multiple integration events when included on the
fragment bearing the transgene.
A shuttle mutagenesis system, which is based on a
derivative of the Escherichia coli transposon Tn3, has been
developed and successfully applied to isolate mutants
defective in filamentous growth and in alkane and fatty
acid utilization [55,56].
Highly representative genomic libraries for use in the S.
cerevisiae two-hybrid system have been generated and
successfully used to demonstrate the interaction between
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the endoplasmic reticulum protein Sls1p and Kar2p, an ER
luminal member of the HSP70 family [57].
4. Y. lipolytica genomics
The Y. lipolytica genome is currently being sequenced in
a collaborative effort, involving several research groups.
Terminal-sequencing of randomly chosen genomic clones
from a plasmid library under the framework of the Geno-
levures project at GENOSCOPE, Centre National de
Sequenage, Evry, France, has yielded 4940 random
sequence tags [58].
Sequencing of the mitochondrial genome of Y. lipolytica
(Fig. 1) has been accomplished by contiging the sequences
of mitochondrial DNA HindIII fragments with sequences
from the Genolevures project and filling the remaining small
gaps by direct sequencing of PCR products [59]. As
expected, this project yielded the sequences of seven com-
plex I subunits (ND1-6, ND4L), one complex III subunit
(apocytochrome B), three complex IV subunits (I, II, III),
three complex V subunits (6, 8, 9) and the large and small
subunits of mitochondrial RNA. Interestingly, the set of
mitochondrial tRNAs is incomplete. There is no tRNA able
to read CGN codon; consequently, such codons are not
found in exonic ORF, while they are still present in some of
the intronic ORFs which therefore must be regarded as
pseudogenes [59].
5. The respiratory chain of Y. lipolytica
The respiratory chain of Y. lipolytica is more similar to its
counterpart from mammals than to that from fermentative
yeasts like S. cerevisiae. The side chain of ubiquinone from
Y. lipolytica is composed of nine isoprenoid units (Q9),
rather than six units (Q6) as in S. cerevisiae [60]. Again in
contrast to S. cerevisiae, Y. lipolytica does possess complex
I, which is composed of an estimated 35 or more subunits
[61]. This proton-pumping NADH:ubiquinone oxidoreduc-
tase is essential for survival of wild-type Y. lipolytica, as
deletions in complex I subunit genes can only be generated
in diploid standard strains and maintained as recessive lethal
alleles in the heterozygous state. This initially presented one
of the major hurdles in establishing Y. lipolytica as a model
system for complex I genetics, which has been overcome
only recently (see below). On the other hand, the fact that
complex I is essential makes Y. lipolytica susceptibile to
Fig. 1. The mitochondrial genome of Y. lipolytica. All genes are encoded on one strand (clockwise orientation). Large (rnl) and small ribosomal RNAs (rns) and
tRNAs are shown in blue, complex I subunits in orange, apocytochrome B in red, complex IV subunits in green, ATP-synthase subunits in purple. Intron
sequences are white, intronic ORFs are shaded in grey (functional), hatched vertically (pseudogenes), or horizontally (untranslatable because of GCN codons).
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complex I inhibitors like 2-decyl-4-quinazolinyl amine
(DQA), thus making Y. lipolytica an attractive model to
screen for inhibitor resistant mutations.
The respiratory chain of Y. lipolytica also contains two
enzymes that are not present in mammals, namely the
‘‘alternative’’ enzymes NDH2 and AOX. NDH2 is a single
subunit NADH:ubiquinone oxidoreductase that carries out
the same redox reaction as complex I but does not contribute
to the transmembrane proton gradient [62]. Unlike complex
I, it does not accept deaminoNADH [63] as an electron
donor. We could demonstrate that in contrast to S. cerevisiae
and N. crassa, there is only one type of alternative NADH-
dehydrogenase present in Y. lipolytica with its NADH
reactive site oriented towards the external face of the
mitochondrial inner membrane [64]. Since most mitochon-
drial redox shuttles described for mammalian [65] and
fungal cells [66,67] that are designed to transport NADH
made in the cytosol into the mitochondrial matrix are not
readily reversible, shuttling of reduction equivalents from
the mitochondrial matrix to the cytosol is problematic.
External orientation, therefore, means that NDH2 cannot
stand in for complex I to oxidize NADH generated in the
mitochondrial matrix. This explains why complex I is an
essential enzyme in Y. lipolytica. NDH2 of Y. lipolytica thus
functions to transfer electrons from cytoplasmic NADH to
the respiratory ubiquinone pool. Deletion of NDH2, how-
ever, did not appreciably affect viability or growth rate on
several complete and minimal media, showing that there
must be redundant pathways that fulfil this role [64].
AOX, the cyanide-resistant alternative terminal oxidase,
is also a single subunit enzyme that carries out electron
transfer from ubiquinol directly to molecular oxygen,
bypassing complexes III and IV [68]. This energy dissipat-
ing and wasteful reaction must be tightly controlled; con-
sequently, AOX activity has only been detected in Y.
lipolytica when complexes III or IV are poisoned. Interest-
ingly, AOX seems to be produced in an inactive form when
cells enter the stationary phase and becomes activated under
stress conditions that dramatically increase the content of
AMP [69].
We have recently cloned AOX from Y. lipolytica (Gen-
Bank accession number AJ428416). The protein sequence
conforms to the requirements of the revised structural model
[70] for the active site of alternative oxidase. According to
this model, the ligands for the hypothetical active site di-
iron centre are located in a four helix bundle, with helices 2
and 3 in an antiparallel orientation to helices 1 and 4. We
conclude that in Y. lipolytica AOX the ligands to the di-iron
centre are E157 (helix 1), E196 and H199 (helix 2), E248
(helix 3) and E301 and H304 (helix 4). E196 and E301 are
the bridging carboxylates, while E157 and E248 are the
terminal ligands. While the two EXXH (X= any amino
acid) motifs in helix 2 and 4 are always present, a third
EXXH motif is found in helix 3 of most alternative
oxidases. The latter motif was proposed to provide two
ligands for the di-iron centre in an earlier model [71], but it
has since become apparent that the histidine of this motif is
not strictly conserved. In Y. lipolytica, like in Trypanosoma
brucei [72], its position is occupied by isoleucine.
A comparison of the inventory of alternative enzymes
present in Y. lipolytica and S. cerevisiae raises some inter-
esting issues. Three NDH2 homologues are present in S.
cerevisiae. Two of them have an external orientation [73],
while one is an internal enzyme [74–76] and may be
regarded as the metabolic substitute for complex I. AOX
is not present in S. cerevisiae and other fermentative yeasts,
indicating that whatever function the enzyme may have in
limiting respiratory chain ATP production or in preventing
the generation of oxygen radicals, it seems to become
obsolete in the absence of complex I.
6. NDH2i: an internal version of NDH2
S. cerevisiae does not need complex I because it contains
an internal alternative NADH:ubiquinone oxidoreductase.
In Aspergillus niger [77] and in N. crassa [4] complex I
deletions are viable, which has been explained by postulat-
ing that these organisms contain an internal NADH-dehy-
drogenase as well. Therefore, we reasoned that constructing
transgenic strains of Y. lipolytica that possess an internal
version of the alternative enzyme might allow for survival of
Y. lipolytica cells lacking functional complex I. A first
attempt using the SCNDI1 gene was unsuccessful since
the S. cerevisiae enzyme obviously was not imported into Y.
lipolytica mitochondria [47]. We then fused the mitochon-
drial targeting sequence of the complex I NUAM subunit to
a truncated version of Y. lipolytica NDH2. The NDH2i
transgene could grow in the presence of up to 10 AM of
the complex I inhibitor DQA and the isolation of haploid
strains carrying deletions in central subunits of complex I
became possible [47]. With respect to NDH2 itself, these
findings strongly suggest that alternative NADH:ubiquinone
oxidoreductases do not require specific proteins for mem-
brane attachment, cofactor insertion and enzymatic function
in Y. lipolytica. It may be speculated that the presence of
one, externally oriented alternative enzyme, as seen in Y.
lipolytica, represents the evolutionary ancestral situation and
that internal NDH2 was recruited by the acquisition of a
mitochondrial targeting sequence [62].
7. Complex I from Y. lipolytica
Complex I from Y. lipolytica is very stable and allows for
straightforward purification. Two different purification pro-
cedures have been developed in our laboratory. One of the
protocols employs ion exchange and size exclusion chro-
matography [61] while the other method is based on His-tag
affinity chromatography [78].
The His-tag purification protocol offers efficient large
scale isolation of highly pure complex I. A hexa-histidine
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sequence was attached to the C terminus of the NUGM (30
kDa) subunit. It was found that the insertion of a hexa-
alanine linker sequence between His-tag and the native C
terminus resulted in slightly stronger binding to the affinity-
column.
Cells grown in a 10-l fermenter are disrupted by a flow-
through cell disintegrator (Euler, Frankfurt, Germany) en-
suring efficient and gentle processing of large quantities of
cells. Mitochondrial membranes are solubilized with laur-
ylmaltoside and applied to a Ni2 + chelating resin. Finally, a
size exclusion step removes residual impurities and re-
chromatography for analytical purposes on the same column
gives rise to a single and symmetric peak. Up to 50 mg of
pure and homogenous protein has been obtained in 1 day by
this method.
The examination of complex I from Y. lipolytica by
electron paramagnetic resonance (EPR) spectroscopy
revealed quite similar characteristics as had been reported
for bovine heart complex I [79] or N. crassa complex I [80].
In the NADH reduced state of purified complex I from Y.
lipolytica five iron sulfur clusters are detectable by EPR
spectroscopy. According to their increasing spin relaxation
rates these clusters were designated N1 ( gz,y,x = 2.018,
1.945, 1.933), N2 ( gz,y,x = 2.051, 1.926, 1.918), N3
( gz,y,x = 2.031, 1.930, 1.861), N4 ( gz,y,x = 2.104, 1.931,
1.892) and N5 ( gz,y,x = 2.062, 1.93, f 1.89) [81,82]. N1
is a [2Fe–2S] cluster showing an EPR spectrum at temper-
atures even above 30 K. Until now, there is no evidence for
the existence of other binuclear clusters like N1a and N1b in
the bovine enzyme [83] or N1a, N1b and N1c in the enzyme
from E. coli [84]. The other clusters in complex I from Y.
lipolytica are of tetranuclear [4Fe–4S] type and can be
detected at temperatures below 20 K. The EPR spectrum
recorded at 12 K shows contributions of four iron sulfur
clusters (Fig. 2). Quantitation based on simulations of the
individual spectra suggests a 1:1:1:1 stoichiometry for these
four clusters. Due to its very high spin relaxation rate,
cluster N5 is only detectable at temperatures below 10 K
and high microwave power. A similar cluster was only
detected in complex I from bovine heart [79] and Rhodo-
bacter sphaeroides [84]. The spin concentration for N5 is
very low as compared to the other four clusters and it is still
a matter of debate whether this EPR signal originates from a
real component of complex I.
As judged by the complex I specific electron transfer rate
from NADH to the artificial electron acceptor hexaammi-
neruthenium(III)-chloride (HAR), the overall yield of the
preparation is 30–40% of the total activity in membranes
and the specific activity is increased by a factor of 70 during
purification [78]. However, the specific NADH:n-decylubi-
quinone (DBQ) oxidoreductase activity did not increase
concomitantly and for the purified enzyme is even lower
than in mitochondrial membranes. The NADH:HAR activ-
ity of complex I was assigned to a three-subunit subcomplex
(flavo-iron–sulfur protein) of the peripheral arm of complex
I [85], while the NADH:DBQ activity employs the entire
electron pathway through the whole complex. Therefore, the
dramatic loss in ubiquinone reductase activity could have
been due to the removal of a functionally essential compo-
nent of the complex during the purification procedure. Since
the purified enzyme was shown to contain bound FMN and
no changes in the EPR spectra of iron sulfur clusters were
detectable [61,78], we analyzed whether a tightly bound
ubiquinone [13] or specific phospholipds were required for
the reaction with hydrophobic ubiquinone: The affinity-
purified complex I from Y. lipolytica was found to contain
0.2–0.4 mol/mol Q9 and 30–60 mol/mol phospholipid
(Dro¨se and Brandt, submitted for publication) and has lost
virtually all of its NADH:DBQ oxidoreductase activity. This
preparation could be reactivated to near membrane levels
also regaining full inhibitor sensitivity by reconstitution into
asolectin (crude chloroform/methanol extract of soy bean
lipids) proteoliposomes [78]. In a more detailed study, we
found that the NADH:DBQ activity could typically be
stimulated from 0.1–0.2 up to 5 Amolmin  1mg  1 by
the addition of 400–500 mol solubilized phospholipids per
Fig. 2. EPR spectrum of complex I from Y. lipolytica. EPR spectrum at 12
K of purified Y. lipolytica complex I after reduction with NADH.
Experimental conditions: microwave frequency, 9.47 GHz; microwave
power, 2 mW; modulation amplitude, 0.8 mT.
Table 1
Stimulation of the NADH:DBQ activity of purified complex I from Y.
lipolytica by asolectin and purified phospholipids
Phospholipid NADH:decylubiquinone
oxidoreductase activity
(Amol min 1 mg 1)
Activation
factor
No addition 0.12 1
Asolectin [20 %
phosphatidylcholine]
4.9 41
Egg yolk
phosphatidylcholine
(> 99%)
4.2 35
Egg yolk
phosphatidylethanolamine
(>99%)
3.1 26
Bovine heart cardiolipin 1.5 13
NADH:DBQ oxidoreductase activity was determined as described in Ref.
[78], using 60 AM DBQ and 100 AM NADH as substrates. Phospholipids
solubilized in 1.6% octyl-h-D-glucopyranoside were added in a [w/w] ratio
of 1:1. (Data from Brandt and Dro¨se, submitted for publication).
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mole of complex I (Dro¨se and Brandt, submitted for
publication). This activity corresponds well with the turn-
over number estimated for mitochondrial membranes (Table
1). Remarkably, almost the same reactivation could be
achieved if highly pure phosphatidylcholine from egg yolk
or other sources was used. With phosphatidylethanolamine
and cardiolipin, lower but still remarkable ubiquinone
reduction rates were obtained (Table 1). We conclude that
affinity purified complex I from Y. lipolytica can be fully
reactivated by adding a layer of neutral phospholipid and
that the loss of activity is not due to extraction of a tightly
bound ubiquinone.
8. Mutagenesis of complex I
Y. lipolytica strains suitable for the genetic analysis of
complex I were generated in the following way: The nuclear
genes NUAM, NUBM, NUCM, NUGM, NUHM, NUIM and
NUKM, encoding the seven central, highly conserved sub-
units of complex I (corresponding to the 75-, 51-, 49-, 30-,
24-kDa, TYKY and PSST subunits from bovine heart
complex I, respectively), were all cloned by the same
strategy: Degenerate primers were designed that correspond
to amino acid stretches strictly conserved between N.
crassa, Bos taurus and Paracoccus denitrificans. The
resulting PCR products were used to screen an ordered
genomic library of Y. lipolytica prepared in plasmid
pBluescriptSK . Sequence analysis demonstrated that all
these genes are intronless in Y. lipolytica. Then, genetically
marked deletions of these seven genes were generated in
diploid cells by homologous recombination with a nuclear
DNA fragment in which the ORF had been replaced by one
of the marker genes URA3 or LEU2. Introduction of the
NDH2i gene on a low-copy plasmid and sporulation yielded
haploid complex I deletion strains. To achieve integration
into the nuclear genome, the NDH2i gene was transformed
as a 4.3-kb SalI fragment into the haploid ndh2D strain
GB5.2, which was chosen since it showed low background
growth on DQA plates. Random integration events which
lead to high NDH2i expression levels, presumably due to
‘‘trapping’’ of nearby enhancers, were selected by their
resistance to 2 and 5 AM DQA.
The chromosomal copy of the NUGM gene encoding the
30-kDa subunit was replaced by the NUGM-HT2 allele in
which the ORF is extended by six alanine and six histidine
codons by the pop-in-pop-out strategy (Fig. 3). This strat-
egy, which is also generally useful for introducing mutations
into genes in their original chromosomal location, consists
of two steps: In the pop-in step, a single homologous
recombination event with the target gene (here: NUGM)
leads to the generation of a tandem repeat, with a marker
Fig. 3. Replacement of the NUGM gene by the NUGM-HT2 allele using the pop-in-pop-out strategy. (A) Pop-in step. A 2.1-kb SalI fragment containing the
NUGM-HT2 gene was subcloned into the XhoI site and a 1.6-kb SalI fragment containing the URA3 marker was subcloned into the SalI site of
pBluescriptSK . The construct was linearized by cutting at the unique SphI site and transformed into Y. lipolytica strain E150. Homologous recombination
results in a direct repeat. (B) Pop-out step. Homologous recombination results in loss of the URA3 marker and either one of the NUGM gene copies. (C)
Monitoring of the pop-in-pop-out strategy by PCR. The primers, which flank the SphI site and the NUGM C-terminus are indicated by arrows in A and B. PI:
pop-in strain; PIPO: pop-in-pop-out strain.
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gene (here: URA3) inserted in between and with one of the
gene copies carrying the desired mutation. In the pop-out
step, recombination between the two repeat units leads to
loss of the marker gene. Negative selection (for loss of the
URA3 marker) is possible by screening for resistance to 5V-
fluoroacetic acid. The remaining copy of the target gene
may be either wild-type or mutated, depending on where the
recombination breakpoint is located. In the case of the
NUKM gene, both the wild-type and the HT2 allele could
be discerned by PCR using a primer pair that flanks the C-
terminal end of the NUKM ORF.
Standard mating and sporulation techniques were then
used to generate haploid strains that carry NDH2i, NUKM-
HT2, and a genetically marked deletion in one of the six
central, nuclear coded genes NUAM, NUBM, NUCM,
NUHM, NUIM and NUKM. Since aneuploid strains may
occur after sporulation in Y. lipolytica, all these strains were
checked for the absence of the corresponding wild-type
gene copy by Southern blot analysis.
Complementation of all complex I deletion strains was
possible by introducing a wild-type copy of the deleted gene
on a low-copy replicative plasmid and could be demonstra-
ted by deaminoNADH:ubiquinone activity of mitochondrial
membranes and or by blue-native gel electrophoresis [86].
Site-directed mutants could then be generated on low-copy
plasmids, but may also be integrated into the genome by
random integration or by homologous recombination with
the wild-type allele. As long as a mutation does not result in
assembly defects or instabilities, no reduction in the expres-
sion levels of complex I has been observed so far.
9. Exploring the catalytic core of complex I from
Y. lipolytica
Several subunits of complex I are homologous to sub-
units of water-soluble [NiFe] hydrogenases from Desulfovi-
brio species [87], for which molecular structures are known
[88,89], and membrane-bound [NiFe] hydrogenases from
various sources [90]. Since this homology has been
reviewed recently [91], it is summarized only briefly here.
The 49-kDa and the PSST subunits of complex I correspond
to the large and small subunits of water-soluble [NiFe]
hydrogenases. In membrane bound [NiFe] hydrogenases,
the small subunit has suffered a deletion that removed two
out of three [4Fe–4S] clusters. These were replaced by two
[4Fe–4S] clusters located in a newly acquired ferredoxin-
like subunit, corresponding to the TYKY subunit in com-
plex I [92].
In recent years, a wealth of experimental data have been
collected that underscore the importance of these evolu-
tionary conserved subunits for enzymatic catalysis in com-
plex I.
Leigh syndrome (subacute necrotizing enzephalomyel-
opathy) may be caused by point mutations in the genes
NDUFS7 [93], encoding the PSST homologue and
NDUFS8 [94], encoding the TYKY homologue. By recon-
struction of these point mutations at the corresponding
positions in complex I from Y. lipolytica, it was found that
the ‘‘Leigh mutant’’ forms of complex I shared common
characteristics: Vmax was reduced by about 50%, subtle
changes in the Km for N-decyl-ubiquinone and the I50 for
hydrophobic inhibitors were observed [95]. Hypertrophic
cardiomyopathy and encephalomyopathy were found to be
associated with mutations in the NDUFS2 gene, encoding
the 49-kDa homologue [96].
A photoreactive derivative of the complex I inhibitor
pyridaben was found to specifically label the PSST subunit
[97] and a ‘‘classical’’ inhibitor resistant mutation (V470M)
was identified in the 49-kDa subunit of complex I from
Rhodobacter capsulatus [98]. The fact that this valine can
be lined up with one of the cysteine ligands for the [NiFe]
active site of the water-soluble hydrogenase from Desulfo-
vibrio species prompted us to investigate whether despite
the lack of the [NiFe] cluster and its cysteine ligands in
complex I and despite low overall sequence similarity, the
active sites of both enzymes were located at corresponding
positions.
Based on this hypothesis, a structural model for the
active site of complex I was constructed by placing the side
chains of residues that are strictly conserved within the 49-
kDa subunit of complex I into the corresponding positions
of the large subunit of the [NiFe] hydrogenase from Desul-
fovibrio fructosovorans [99]. When this model was tested
by site-directed mutagenesis of these residues, basically two
types of effect were found: Resistance to complex I inhib-
itors like rotenone and DQA was observed with mutations
that cluster around the former [NiFe] site, while effects on
the EPR signal of cluster N2 were observed with mutations
that map closer to the interface with the PSST homologous
subunit [100]. Similarly, we could demonstrate that muta-
tions that replace acidic residues within the PSST homo-
logue with the corresponding amide displayed effects on the
EPR signal of cluster N2 [101]. The fact that the molecular
phenotypes of the complex I mutants followed a spatial
gradient pattern consistent with their positions in the D.
fructosovorans [NiFe] hydrogenase led us to conclude that
the overall structural fold is evolutionary conserved between
these two enzymes. Our structural model implies that the
ubiquinone binding site of complex I was at least in part
derived from the active site of [NiFe] hydrogenases and that
cluster N2, which has been proposed to be directly involved
in proton pumping [12,13], is located in the PSST homo-
logue and corresponds to the proximal [4Fe–4S] cluster of
[NiFe] hydrogenases.
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